As in GBM patients, IDH protein mutation is associated with improved PFS (progression-free survival) and OS (overall survival) rate so this aberration is considered as one of the most important molecular prognostic biomarker of GBM [49]. This evidence concerns the gene IDH2 and glioblastoma.